Company profile for Pathalys Pharma

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Pathalys is a private, late-stage clinical biopharmaceutical company committed to the development of multiple advanced therapeutics that address unmet needs in the management of late stage chronic kidney disease (CKD).The most common causes of SHPT are kidney failure and vitamin D deficiency. In kidney failure, the kidney is no longer able to make enough vitamin D or remove all the phosphorus that is made by the body, which le...
Pathalys is a private, late-stage clinical biopharmaceutical company committed to the development of multiple advanced therapeutics that address unmet needs in the management of late stage chronic kidney disease (CKD).The most common causes of SHPT are kidney failure and vitamin D deficiency. In kidney failure, the kidney is no longer able to make enough vitamin D or remove all the phosphorus that is made by the body, which leads to low calcium levels.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
4242 Six Forks Road Suite 820 Raleigh, NC 27609
Telephone
Telephone
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.fiercebiotech.com/biotech/pathalys-raises-105m-series-b-prepare-japan-approved-kidney-disease-drug-fda

FIERCE BIOTECH
21 Aug 2024

https://www.prnewswire.com/news-releases/pathalys-pharma-appoints-dr-bastian-dehmel-as-chief-medical-officer-302220827.html

PR NEWSWIRE
13 Aug 2024

https://www.prnewswire.com/news-releases/pathalys-pharma-and-launch-therapeutics-announce-first-patient-enrolled-ahead-of-schedule-in-pivotal-phase-3-program-for-upacicalcet-in-patients-receiving-hemodialysis-301838534.html

PR NEWSWIRE
31 May 2023

https://endpts.com/pathalys-inks-development-deal-with-abingworth-company-raising-150m/

Paul Schloesser ENDPTS
18 Jan 2023

https://www.prnewswire.com/news-releases/pathalys-pharma-raises-150-million-in-secured-product-financing-and-equity-led-by-abingworth-forms-strategic-collaboration-with-launch-therapeutics-to-advance-upacicalcet-through-pivotal-phase-3-studies-301724617.html

PR NEWSWIRE
18 Jan 2023

https://www.prnewswire.com/news-releases/pathalys-pharma-to-present-at-jefferies-healthcare-conference-301559993.html

PRNEWSWIRE
02 Jun 2022

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty